You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

329 Results
Regimen
Cancer Type:
Central Nervous System
Intent: Adjuvant, Palliative
Funding:
ODB - General Benefit
    lomustine
May 2019
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Sep 2022
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
Exceptional Access Program
    ceritinib - Second-line monotherapy of ALK-positive locally advanced (not amenable to curative therapy) or metastatic NSCLC, in patients who have experienced disease progression or intolerance to crizotinib, according to specific criteria
Nov 2024
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Funding:
ODB - General Benefit
    chlorambucil
Nov 2024
Regimen
Regimen
Cancer Type:
Skin, 
Squamous Cell
Intent: Palliative
Jul 2023
Regimen
Cancer Type:
Hematologic, 
Lymphoma - T-cell
Intent: Curative, Palliative
May 2019
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
May 2019
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Palliative
Apr 2023
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Cancer Type:
Gynecologic, 
Vulva
Intent: Neoadjuvant, Palliative
Oct 2017
Regimen
Cancer Type:
Hematologic, 
Leukemia - Hairy Cell, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Maintenance Treatment - Lymphoma
Aug 2020

Pages